Zoetis Inc. $ZTS Shares Sold by E. Ohman J or Asset Management AB

E. Ohman J or Asset Management AB cut its position in Zoetis Inc. (NYSE:ZTS) by 9.6% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 18,212 shares of the company’s stock after selling 1,938 shares during the period. E. Ohman J or Asset Management AB’s holdings in Zoetis were worth $2,840,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently added to or reduced their stakes in the company. Portside Wealth Group LLC grew its stake in Zoetis by 24.7% during the 1st quarter. Portside Wealth Group LLC now owns 33,709 shares of the company’s stock valued at $5,550,000 after acquiring an additional 6,672 shares in the last quarter. Tandem Investment Advisors Inc. increased its holdings in shares of Zoetis by 100.3% in the first quarter. Tandem Investment Advisors Inc. now owns 395,626 shares of the company’s stock valued at $65,140,000 after purchasing an additional 198,089 shares during the last quarter. Flagship Harbor Advisors LLC lifted its position in Zoetis by 31.2% during the first quarter. Flagship Harbor Advisors LLC now owns 7,394 shares of the company’s stock worth $1,217,000 after buying an additional 1,760 shares in the last quarter. Horizon Financial Services LLC acquired a new position in Zoetis during the first quarter worth $380,000. Finally, Sage Rhino Capital LLC boosted its stake in Zoetis by 117.6% during the first quarter. Sage Rhino Capital LLC now owns 7,014 shares of the company’s stock worth $1,155,000 after buying an additional 3,791 shares during the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Stifel Nicolaus lowered Zoetis from a “buy” rating to a “hold” rating and reduced their price target for the stock from $165.00 to $160.00 in a report on Wednesday, June 18th. Argus reaffirmed a “buy” rating and set a $190.00 target price on shares of Zoetis in a research note on Tuesday, September 9th. Leerink Partnrs lowered shares of Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Piper Sandler raised their price target on shares of Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Finally, Leerink Partners cut Zoetis from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $180.00 to $155.00 in a report on Thursday, July 17th. Five equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, Zoetis currently has a consensus rating of “Moderate Buy” and an average price target of $200.88.

Zoetis Stock Performance

Shares of ZTS opened at $146.34 on Tuesday. The stock has a 50 day moving average price of $152.10 and a 200 day moving average price of $157.06. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. The company has a market capitalization of $64.85 billion, a price-to-earnings ratio of 25.19, a price-to-earnings-growth ratio of 2.38 and a beta of 0.89. Zoetis Inc. has a 52-week low of $139.70 and a 52-week high of $200.33.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, topping analysts’ consensus estimates of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The company had revenue of $2.46 billion for the quarter, compared to analysts’ expectations of $2.41 billion. During the same quarter last year, the company earned $1.56 earnings per share. The firm’s revenue for the quarter was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Research analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.